These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 30460518)

  • 1. Apixaban Levels in Octogenarian Patients with Non-valvular Atrial Fibrillation.
    Nissan R; Spectre G; Hershkovitz A; Green H; Shimony S; Cooper L; Nakav S; Shochat T; Grossman A; Fuchs S
    Drugs Aging; 2019 Feb; 36(2):165-177. PubMed ID: 30460518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Laboratory measurement of apixaban using anti-factor Xa assays in acute ischemic stroke patients with non-valvular atrial fibrillation.
    Shin H; Cho MC; Kim RB; Kim CH; Choi NC; Kim SK; Koh EH
    J Thromb Thrombolysis; 2018 Feb; 45(2):250-256. PubMed ID: 29198080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Anti-factor Xa Activity Among Three Different Factor Xa Inhibitors in Non-valvular Atrial Fibrillation Patients with Renal Impairment.
    Tobe A; Osanai H; Tanaka A; Sakaguchi T; Kambara T; Nakashima Y; Asano H; Ishii H; Ajioka M; Murohara T
    Clin Drug Investig; 2020 Jun; 40(6):567-573. PubMed ID: 32314297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurement of Anti-Factor Xa Activity in Patients on Apixaban for Non-Valvular Atrial Fibrillation.
    Osanai H; Ajioka M; Masutomi T; Kuwayama T; Ishihama S; Sakamato Y; Otaka N; Sakaguchi T; Inoue Y; Kanbara T; Nakashima Y; Asano H; Sakai K
    Circ J; 2015; 79(12):2584-90. PubMed ID: 26439323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical evaluation of laboratory methods to monitor apixaban treatment in patients with atrial fibrillation.
    Skeppholm M; Al-Aieshy F; Berndtsson M; Al-Khalili F; Rönquist-Nii Y; Söderblom L; Östlund AY; Pohanka A; Antovic J; Malmström RE
    Thromb Res; 2015 Jul; 136(1):148-53. PubMed ID: 25981142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interindividual Variability of Apixaban Plasma Concentrations: Influence of Clinical and Genetic Factors in a Real-Life Cohort of Atrial Fibrillation Patients.
    Roşian AN; Roşian ŞH; Kiss B; Ştefan MG; Trifa AP; Ober CD; Anchidin O; Buzoianu AD
    Genes (Basel); 2020 Apr; 11(4):. PubMed ID: 32316515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apixaban Concentrations with Lower than Recommended Dosing in Older Adults with Atrial Fibrillation.
    Sukumar S; Gulilat M; Linton B; Gryn SE; Dresser GK; Alfonsi JE; Schwarz UI; Kim RB; Schwartz JB
    J Am Geriatr Soc; 2019 Sep; 67(9):1902-1906. PubMed ID: 31112620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial.
    Ng KH; Shestakovska O; Connolly SJ; Eikelboom JW; Avezum A; Diaz R; Lanas F; Yusuf S; Hart RG
    Age Ageing; 2016 Jan; 45(1):77-83. PubMed ID: 26590293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of global laboratory methods and establishing on-therapy ranges for monitoring apixaban and rivaroxaban: Experience at a single institution.
    Park SH; Seo YH; Park PW; Kim KH; Seo JY; Lee HT; Kwoun WJ; Ahn JY
    J Clin Lab Anal; 2019 Jun; 33(5):e22869. PubMed ID: 30860622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial.
    Hu PT; Lopes RD; Stevens SR; Wallentin L; Thomas L; Alexander JH; Hanna M; Lewis BS; Verheugt FW; Granger CB; Jones WS
    J Am Heart Assoc; 2017 Jan; 6(1):. PubMed ID: 28096100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coagulation markers in patients with venous thromboembolism treated with 10 mg apixaban twice daily.
    Ono R; Fukushima K; Yamazaki T; Yamashita D; Takahashi H; Hori Y; Nishimura K
    Naunyn Schmiedebergs Arch Pharmacol; 2022 Feb; 395(2):159-166. PubMed ID: 34851448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical implications of assessment of apixaban levels in elderly atrial fibrillation patients: J-ELD AF registry sub-cohort analysis.
    Suzuki S; Yamashita T; Akao M; Okumura K;
    Eur J Clin Pharmacol; 2020 Aug; 76(8):1111-1124. PubMed ID: 32451850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation.
    Andersson NW; Svanström H; Lund M; Pasternak B; Melbye M
    Int J Cardiol; 2018 Oct; 268():113-119. PubMed ID: 29934230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apixaban enhances endogenous fibrinolysis in patients with atrial fibrillation.
    Spinthakis N; Gue Y; Farag M; Srinivasan M; Wellsted D; Arachchillage DRJ; Lip GYH; Gorog DA
    Europace; 2019 Sep; 21(9):1297-1306. PubMed ID: 31505618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of hospital length of stay between hospitalized non-valvular atrial fibrillation patients treated with either apixaban or warfarin.
    Farr AM; Jing Y; Johnston S; Trocio J; Singhal S; Bruno A; Graham J
    Hosp Pract (1995); 2015; 43(3):172-9. PubMed ID: 26213178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dabigatran but not rivaroxaban or apixaban treatment decreases fibrinolytic resistance in patients with atrial fibrillation.
    Semeraro F; Incampo F; Ammollo CT; Dellanoce C; Paoletti O; Testa S; Colucci M
    Thromb Res; 2016 Feb; 138():22-29. PubMed ID: 26826504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of apixaban therapy and prothrombin time in patients with atrial fibrillation.
    Kanemoto M; Kuhara H; Ueda T; Shinohara T; Oda T; Nakao F; Kamei T; Ikeda Y; Fujii T
    Circ J; 2014; 78(11):2651-6. PubMed ID: 25253621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial.
    Cowper PA; Sheng S; Lopes RD; Anstrom KJ; Stafford JA; Davidson-Ray L; Al-Khatib SM; Ansell J; Dorian P; Husted S; McMurray JJV; Steg PG; Alexander JH; Wallentin L; Granger CB; Mark DB
    JAMA Cardiol; 2017 May; 2(5):525-534. PubMed ID: 28355434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and safety of apixaban therapy in daily-care patients with atrial fibrillation: results from the Dresden NOAC Registry.
    Helmert S; Marten S; Mizera H; Reitter A; Sahin K; Tittl L; Beyer-Westendorf J
    J Thromb Thrombolysis; 2017 Aug; 44(2):169-178. PubMed ID: 28643004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-Xa Oral Anticoagulant Plasma Concentration Assay in Real Life: Rivaroxaban and Apixaban Quantification in Emergency With LMWH Calibrator.
    Billoir P; Barbay V; Joly LM; Fresel M; Chrétien MH; Le Cam Duchez V
    Ann Pharmacother; 2019 Apr; 53(4):341-347. PubMed ID: 30378443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.